EN DE
Watch Pharmhouse Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pharmhouse Corp (PHSE) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Pharmhouse Corp stock $0.01, price $0.02, that is 19.0% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Cyclical US

PC Pharmhouse Corp logo Thin data Nov 10, 2026

Pharmhouse Corp

PHSE · US
Expensive, weak quality

Our calculation puts a fair price 19% below what the stock costs today.

Fair value $0.0133 · Overvalued
Quality 26/100
Weak Growth
Loss-making · -35.3% net margin (TTM)
Negative free cash flow
Trails peers (3/8)
Narrow moat 21/100 · thin data
Thin data
Estimate
Watch Pharmhouse Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.90 $0.0011 Fair Value $0.0133 Nov 2018 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.0011 – $1.90 · fair‑value band $0.0129 – $0.0137 · the $0.0164 price screens above the $0.0133 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Pharmhouse in your weekly email

Every Wednesday you see whether Pharmhouse is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pride Holdings Group operates as a LGBTQ-focused entertainment, hospitality, and lifestyle company in the United States. It engages in the bar, pub, tavern, restaurant, hotels, nightclubs, and live adult entertainment industry businesses.

Show moreShow less

The company was formerly known as Parliament House Enterprises, Inc. and changed its name to Pride Holdings Group in July 2025. Pride Holdings Group is based in Orlando, Florida.

Stock analysis

Pharmhouse Corp (PHSE) currently trades at $0.0164, while our estimate is $0.0133, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0129 (bear) to $0.0137 (bull), the price of $0.0164 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Consumer Cyclical sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Pharmhouse Corp reported revenue of $3.0M in FY2025 versus $10.7K in FY2016, a compound +87.1%/yr. Reported net income was −$9.4M in FY2025.

Key figures

Market cap $37.4M Micro · EPS (TTM) $−0.0100 · Net margin −35.3% · Return on equity −56.7% · Return on assets (EBIT) −104% (5-year average) · Operating margin 19.6% · Revenue growth (YoY) +191% · Free cash flow −$2.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 93% below its 52-week high and 173% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Cyclical peers we cover trades at −29% fair-value upside, at −19%, PHSE screens cheaper than that median.

Fair Value

Bear $0.0129 Fair Value $0.0133 Bull $0.0137
Price $0.0164 · Downside -19.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 88
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−30.9% (2018) → −301.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PHSE screens overvalued: fair value 19% below the price. Compare with Marriott International, Inc →

Compare Pharmhouse Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Lodging · 164 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −18.9% · Below median
Profitability
Return on assets −15.6% · Bottom 25%
Net margin (12 months) −35.3% · Bottom 25%
Operating margin (12 months) 19.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 190.8% · Top 25%

Valuation Multiplesvs Lodging median · lower = cheaper

P/B 0.72× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 20
FUTURE (revenue growth)100 · sector 30
PAST (return on equity)0 · sector 14
HEALTH (low debt)0 · sector 89
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Lodging stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Atour Lifestyle Holdings ATAT $36.05 $58.26 +62% vs PHSE
H World Group 1179 HK$39.74 HK$50.55 +27% vs PHSE
Jabal Omar Development Company 4250 15.96 SAR 17.95 SAR +12% vs PHSE
Accor SA AC €52.44 €41.40 −21% vs PHSE
Hilton Worldwide Holdings HLT $379.76 $271.08 −29% vs PHSE
Choice Hotels International, Inc CHH $120.23 $75.26 −37% vs PHSE
The Indian Hotels Company INDHOTEL ₹891.65 ₹502.32 −44% vs PHSE
Hyatt Hotels Corporation H $191.55 $86.67 −55% vs PHSE
Wyndham Hotels & Resorts, Inc WH $81.12 $29.61 −64% vs PHSE
Marriott International, Inc MAR $428.26 $151.21 −65% vs PHSE

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharmhouse Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pharmhouse Corp Fair Value". https://www.fairvalue-calculator.com/stock/PHSE

Frequently asked questions

Is Pharmhouse Corp (PHSE) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0133 versus a price of $0.0164, about 19% lower (overvalued).
What is the fair value of PHSE?
Our estimate for Pharmhouse Corp is $0.0133 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.0164.
What is the quality score of PHSE?
Pharmhouse Corp has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmhouse Corp (PHSE)?
Our calculated price target is the estimate of $0.0133 (as of Nov 10, 2026). Cautious scenario $0.0129, optimistic scenario $0.0137. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pharmhouse Corp stock forecast for 2026?
Our estimate puts fair value at $0.0133, about 19% lower versus a price of $0.0164 (overvalued). Cautious scenario $0.0129, optimistic scenario $0.0137. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Pharmhouse Corp (PHSE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmhouse Corp it is $0.0133 per share (as of Nov 10, 2026), against a price of $0.0164.
Is Pharmhouse Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PHSE trades above its calculated fair value: price $0.0164, fair value $0.0133, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PHSE?
No. The price is what the market pays today ($0.0164); the fair value is what the company's own numbers justify ($0.0133). For Pharmhouse Corp the two are $0.0031 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmhouse Corp worth?
The market values Pharmhouse Corp at about $37.4M (market capitalisation, as of Nov 10, 2026). Per share that is $0.0164; our models calculate a fair value of $0.0133 per share.
What do the bullish and bearish scenarios say about PHSE?
Our models span a range for Pharmhouse Corp: cautious scenario $0.0129, base $0.0133, optimistic $0.0137 per share (as of Nov 10, 2026, price $0.0164). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmhouse Corp (PHSE)?
Balance-sheet figures for Pharmhouse Corp (as of Nov 10, 2026): return on equity −56.7%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is PHSE from its 52-week high?
Pharmhouse Corp trades at $0.0164, about 93% below its 52-week high of $0.2200 and 173% above the low of $0.0060 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0133 is for.
Which stocks are comparable to Pharmhouse Corp?
From the same area (Consumer Cyclical) we also value Marriott International, Inc, Hilton Worldwide Holdings, Hyatt Hotels Corporation, H World Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmhouse Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $0.0164, calculated fair value $0.0133 (−19%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Pharmhouse Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmhouse Corp (PHSE)?
The closing price on Nov 10, 2026 was $0.0164. Our estimate is $0.0133, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmhouse Corp right now?
The price sits above even our optimistic bull case ($0.0137). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band ($0.0129 to $0.0137), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pharmhouse Corp

How large is the market capitalisation of Pharmhouse Corp (PHSE)?
The market capitalisation of Pharmhouse Corp is $37.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Pharmhouse Corp (PHSE)?
Earnings per share at Pharmhouse Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pharmhouse Corp (PHSE)?
The net margin of Pharmhouse Corp is −35.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmhouse Corp (PHSE)?
The return on equity (ROE) of Pharmhouse Corp is −56.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmhouse Corp (PHSE)?
On an EBIT basis the return on assets of Pharmhouse Corp is −104% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmhouse Corp (PHSE)?
The operating margin of Pharmhouse Corp is 19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmhouse Corp (PHSE)?
Revenue at Pharmhouse Corp is growing +191% versus a year earlier (3y avg +661%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pharmhouse Corp (PHSE) generate?
The free cash flow of Pharmhouse Corp is −$2.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmhouse Corp (PHSE) carry?
The net debt of Pharmhouse Corp is $4.7M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pharmhouse Corp in the live analysis

One click puts Pharmhouse Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.